Breast cancer
Conditions
Interventions
Group L:Intravenous Lidocaine
Group S:Intravenous infusion of 0.9% saline
Sponsors
The Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-85 years; female patients; 2. Planned elective unilateral breast cancer radical mastectomy; 3. Frozen pathological sections were diagnosed as primary invasive breast cancer (TNM staging: T1-3, N0-2, M0); 4. Agree to participate in this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Those who are allergic to local anesthetics such as lidocaine; 2. Patients with a history of chemotherapy or radiotherapy and secondary surgery (recurrence or reconstruction); 3. Metastatic breast cancer, inflammatory breast cancer; 4. BMI>30kg/m^2; 5. Endocrine system diseases, autoimmune diseases, immunodeficiency diseases, other active cancers and recent (<1 month) infection history, or patients with ASA IV-V, leukemia, etc. or long-term use of immunosuppressants; 6. Unable to cooperate with the researcher for any reason: hearing or visual impairment, language comprehension impairment, mental illness, etc.; 7. Pregnant or breastfeeding; 8. Combined with central neuropathy, liver and kidney dysfunction and hypotension (systolic blood pressure <= 90 mmHg); 9. Participate in other researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of NK cells; | — |
Secondary
| Measure | Time frame |
|---|---|
| T lymphocyte subsets;QOR-15 score at 24 hours after operation;Incidence of postoperative chronic pain;The incidence of postoperative adverse events; | — |
Countries
China
Contacts
Public ContactWang Zhiping
Xuzhou Medical University
Outcome results
None listed